If a variant has more than one submission, it may be counted in more than one significance column. If this is the
case, the total number of variants will be less than the sum of the other cells.
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
association |
risk factor |
not provided |
total |
323
|
46
|
296
|
136
|
76
|
3
|
1
|
10
|
886
|
Gene and significance breakdown #
Total genes and gene combinations: 66
Gene or gene combination |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
association |
risk factor |
not provided |
total |
APC
|
91
|
3
|
72
|
26
|
23
|
0 |
1
|
0 |
213
|
MSH6
|
44
|
6
|
32
|
27
|
10
|
0 |
0 |
0 |
119
|
MSH2
|
51
|
7
|
26
|
9
|
9
|
0 |
0 |
0 |
102
|
MLH1
|
42
|
13
|
13
|
8
|
4
|
0 |
0 |
0 |
80
|
MUTYH
|
19
|
3
|
15
|
8
|
4
|
0 |
0 |
0 |
47
|
POLE
|
2
|
0 |
11
|
16
|
7
|
0 |
0 |
0 |
36
|
POLD1
|
0 |
0 |
8
|
12
|
11
|
0 |
0 |
0 |
31
|
PALB2
|
0 |
1
|
23
|
2
|
0 |
0 |
0 |
0 |
26
|
PMS2
|
11
|
1
|
7
|
4
|
1
|
0 |
0 |
0 |
24
|
KDR
|
0 |
0 |
14
|
0 |
0 |
0 |
0 |
0 |
14
|
AXIN2
|
2
|
1
|
9
|
0 |
1
|
0 |
0 |
0 |
13
|
FLT4, LOC126807632
|
0 |
0 |
13
|
0 |
0 |
0 |
0 |
0 |
13
|
ATM
|
1
|
1
|
2
|
4
|
2
|
0 |
0 |
0 |
10
|
FGFR3
|
7
|
0 |
3
|
0 |
0 |
0 |
0 |
0 |
10
|
TP53
|
3
|
2
|
5
|
0 |
0 |
0 |
0 |
0 |
10
|
FLT4
|
0 |
0 |
8
|
1
|
0 |
0 |
0 |
0 |
9
|
BUB1B
|
1
|
0 |
7
|
0 |
0 |
0 |
0 |
0 |
8
|
FLCN
|
3
|
1
|
4
|
0 |
0 |
0 |
0 |
0 |
8
|
FLT1
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
7
|
8
|
ATM, C11orf65
|
1
|
0 |
3
|
3
|
0 |
0 |
0 |
0 |
7
|
EP300
|
4
|
0 |
1
|
1
|
1
|
0 |
0 |
0 |
7
|
PIK3CA
|
5
|
0 |
2
|
0 |
0 |
0 |
0 |
0 |
7
|
BRAF
|
5
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5
|
BRCA2
|
0 |
2
|
2
|
1
|
0 |
0 |
0 |
0 |
5
|
BMPR1A
|
0 |
0 |
1
|
3
|
0 |
0 |
0 |
0 |
4
|
PPARG
|
4
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4
|
SMAD4
|
2
|
0 |
0 |
2
|
0 |
0 |
0 |
0 |
4
|
intergenic
|
0 |
0 |
0 |
0 |
0 |
3
|
0 |
0 |
3
|
BARD1
|
0 |
0 |
2
|
1
|
0 |
0 |
0 |
0 |
3
|
CDH1
|
0 |
0 |
3
|
0 |
0 |
0 |
0 |
0 |
3
|
CHEK2
|
0 |
1
|
2
|
0 |
0 |
0 |
0 |
0 |
3
|
CTNNB1, LOC126806658
|
3
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3
|
FLT1, LOC126861720
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3
|
3
|
PTEN
|
0 |
0 |
0 |
3
|
0 |
0 |
0 |
0 |
3
|
STK11
|
0 |
0 |
1
|
2
|
0 |
0 |
0 |
0 |
3
|
BAX
|
2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
BRCA1
|
1
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
2
|
BRIP1
|
0 |
1
|
0 |
0 |
1
|
0 |
0 |
0 |
2
|
EPCAM
|
2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
MCC
|
2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
PTPRJ
|
2
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2
|
RAD51C
|
0 |
0 |
2
|
0 |
0 |
0 |
0 |
0 |
2
|
AKT1
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
AOPEP, FANCC
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
APC, LOC129994371
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
BCL10
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
BRCA1, LOC126862571
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
BUB1
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
DCC
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
DLC1
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
FANCE
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
LOC129933707, LOC129933708, MSH6
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
LOC130009266, POLE
|
0 |
0 |
0 |
0 |
1
|
0 |
0 |
0 |
1
|
LOC130062899, STK11
|
0 |
0 |
0 |
1
|
0 |
0 |
0 |
0 |
1
|
MLH3
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
MT-ND1
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
MUTYH, TOE1
|
0 |
0 |
0 |
1
|
0 |
0 |
0 |
0 |
1
|
NBN
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
NRAS
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
PDGFRA
|
0 |
0 |
0 |
0 |
1
|
0 |
0 |
0 |
1
|
PDGFRL
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
PTPN12
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
RAD51D, RAD51L3-RFFL
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
RAD54B
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
RAD54L
|
1
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1
|
REV3L
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Submitter and significance breakdown #
Submitter |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
association |
risk factor |
not provided |
total |
Department of Pathology and Laboratory Medicine, Sinai Health System
|
255
|
33
|
174
|
133
|
73
|
0 |
0 |
0 |
668
|
Fulgent Genetics, Fulgent Genetics
|
20
|
3
|
49
|
0 |
2
|
0 |
0 |
0 |
74
|
Immunobiology Lab; University of Kashmir
|
0 |
0 |
35
|
0 |
0 |
0 |
0 |
10
|
45
|
OMIM
|
43
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
43
|
Leiden Open Variation Database
|
0 |
0 |
19
|
0 |
0 |
0 |
0 |
0 |
19
|
3DMed Clinical Laboratory Inc
|
6
|
0 |
13
|
0 |
0 |
0 |
0 |
0 |
19
|
Pathway Genomics
|
8
|
1
|
3
|
1
|
1
|
0 |
0 |
0 |
14
|
Genetic Predisposition to Colorectal Cancer Group, Institut d’Investigacions Biomediques August Pi i Sunyer
|
0 |
6
|
0 |
0 |
0 |
0 |
0 |
0 |
6
|
Labcorp Genetics (formerly Invitae), Labcorp
|
2
|
0 |
1
|
1
|
1
|
0 |
0 |
0 |
5
|
Colorectal Cancer Research Lab, Singapore General Hospital
|
0 |
0 |
0 |
0 |
0 |
3
|
0 |
0 |
3
|
Mendelics
|
0 |
0 |
1
|
1
|
0 |
0 |
0 |
0 |
2
|
Cancer Genetics Service, National Cancer Centre Singapore
|
0 |
0 |
2
|
0 |
0 |
0 |
0 |
0 |
2
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Genomic Research Center, Shahid Beheshti University of Medical Sciences
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Clinical Genomics Laboratory, Washington University in St. Louis
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
CSER _CC_NCGL, University of Washington
|
0 |
0 |
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Department of Molecular and Medical Genetics, Osaka Medical Center for Cancer and Cardiovascular Diseases
|
0 |
1
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
Snyder Lab, Genetics Department, Stanford University
|
0 |
0 |
0 |
0 |
0 |
0 |
1
|
0 |
1
|
The information on this website is not intended for direct
diagnostic use or medical decision-making without review by a
genetics professional. Individuals should not change their
health behavior solely on the basis of information contained on
this website. Neither the University of Utah nor the National
Institutes of Health independently verfies the submitted
information. If you have questions about the information
contained on this website, please see a health care
professional.